Literature DB >> 27540426

Comparison of the Performances of (18)F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study.

SangDon Kwon1, KyungAh Chun1, EunJung Kong1, IhnHo Cho1.   

Abstract

PURPOSE: (18)F-FP-CIT [(18)F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane] has been well established and used for the differential diagnosis of atypical parkinsonian disorders. Recently, combined positron emission tomography (PET)/magnetic resonance (MR) was proposed as a viable alternative to PET/computed tomography (CT). The aim of this study was to compare the performances of conventional (18)F-FP-CIT brain PET/CT and simultaneous PET/MR by visual inspection and quantitative analysis. <br> METHODS: Fifteen consecutive patients clinically suspected of having Parkinson's disease were recruited for the study.(18)F-FP-CIT PET was performed during PET/CT and PET/MR. PET/CT image acquisition was started 90 min after intravenous injection of (18)F-FP-CIT and then PET/MR images were acquired. Dopamine transporter (DAT) density in bilateral striatal subregions was assessed visually. Quantitative analyses were performed on bilateral striatal volumes of interest (VOIs) using average standardized uptake values (SUVmeans). Intraclass correlation coefficients (ICCs) and their 95 % confidence intervals (CIs) were assessed to compare PET/CT and PET/MR data. Bland-Altman plots were drawn to perform method-comparisons. <br> RESULTS: All subjects showed a preferential decrease in DAT binding in the posterior putamen (PP), with relative sparing of the ventral putamen (VP). Bilateral striatal subregional binding ratio (BR) determined PET/CT and PET/MR demonstrated close interequipment correspondence (BRright caudate - ICC, 0.944; 95 % CI, 0.835-0.981, BRleft caudate - ICC, 0.917; 95 % CI, 0.753-0.972, BRright putamen - ICC, 0.976; 95 % CI, 0.929-0.992 and BRleft putamen - ICC, 0.970; 95 % CI, 0.911-0.990, respectively), and Bland-Altman plots showed interequipment agreement between the two modalities. <br> CONCLUSIONS: It is known that MR provides more information about anatomical changes associated with brain diseases and to enable the anatomical allocations of subregions than CT, though this was not observed in the present study. Although the subregional BR of simultaneous PET/MR was comparable to that of PET/CT in Parkinson's disease, our isocontouring method could make bias. A future automated method using standard template study or manual segmentation of putamen/caudate based on MR or CT is needed.

Entities:  

Keywords:  18F-FP-CIT; Dopamine transporter; PET/CT; PET/MR

Year:  2016        PMID: 27540426      PMCID: PMC4977258          DOI: 10.1007/s13139-016-0419-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  36 in total

Review 1.  Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques.

Authors:  Matthias Hofmann; Bernd Pichler; Bernhard Schölkopf; Thomas Beyer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 2.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 3.  Parkinson's disease. Second of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

4.  Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology.

Authors:  Axel Martinez-Möller; Matthias Eiber; Stephan G Nekolla; Michael Souvatzoglou; Alexander Drzezga; Sibylle Ziegler; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

5.  Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography.

Authors:  Maqsood Yaqub; Ronald Boellaard; Bart N M van Berckel; Mirthe M Ponsen; Mark Lubberink; Albert D Windhorst; Henk W Berendse; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2006-12-27       Impact factor: 6.200

6.  Statistical methodology for the concurrent assessment of interrater and intrarater reliability: using goniometric measurements as an example.

Authors:  M Eliasziw; S L Young; M G Woodbury; K Fryday-Field
Journal:  Phys Ther       Date:  1994-08

7.  Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner.

Authors:  Gaspar Delso; Sebastian Fürst; Björn Jakoby; Ralf Ladebeck; Carl Ganter; Stephan G Nekolla; Markus Schwaiger; Sibylle I Ziegler
Journal:  J Nucl Med       Date:  2011-11-11       Impact factor: 10.057

8.  Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.

Authors:  Minyoung Oh; Jae Seung Kim; Ji Young Kim; Kwang-Ho Shin; Seol Hoon Park; Hye Ok Kim; Dae Hyuk Moon; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  J Nucl Med       Date:  2012-02-09       Impact factor: 10.057

9.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?

Authors:  Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

10.  Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.

Authors:  Pekka Jokinen; Hans Helenius; Elina Rauhala; Anna Brück; Olli Eskola; Juha O Rinne
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

View more
  1 in total

Review 1.  Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

Authors:  Chae-Moon Hong; Ho-Sung Ryu; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.